Cipla licenses Eli Lilly’s CoViD drug baricitinib for Indian market

Cipla licenses Eli Lilly’s CoViD drug baricitinib for Indian market

Generic drugmaker Cipla has signed a licensing agreement with Eli Lilly and Co., to manufacture and sell the latter’s arthritis drug baricitinib, now repurposed as a drug for the treatment of CoViD-19. Baricitinib has been given ‘Restricted Emergency Use’ approval by India’s drug regulator Central Drugs Standard Control Organisation (CDSCO) for use in combination with remdesivir for CoViD-treatment. The Cipla-Lilly license agreement is a royalty free and non-exclusive voluntary one and it can improve the availability of the drug for adult CoViD-patients requiring supplemental oxygen, invasive ventilation or extracorporeal membrane oxygenation.

Eli Lilly, the research based US drugmaker had already received an ‘Emergency Use Approval’ from the US Food and Drug Administration in November 2020 for using baricitinib along with remdesivir to treat CoViD-19 patients.